|
||||||
|
 | |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
|
Gene: ENSG00000185624 |
Summary for P4HB |
 Gene summary |
| Gene information | Ensembl ID | ENSG00000185624 | Gene symbol | P4HB |
| Gene name | prolyl 4-hydroxylase subunit beta | |
| HGNC | 8548 | |
| Entrez ID | 5034 | |
| Gene type | protein_coding | |
| Synonyms | P4HB|PDIA1|PROHB|DSI|GIT|PDI|PO4HB|P4Hbeta | |
| UniProtAcc | P07237 |
| Drugs associated with this gene(DrugBank). |
| Gene ID | Gene Symbol | Drug ID | Drug Name | Drug Type |
| ENSG00000185624 | P4HB | DB01593 | Zinc | SmallMoleculeDrug |
| ENSG00000185624 | P4HB | DB03615 | Ribostamycin | SmallMoleculeDrug |
| ENSG00000185624 | P4HB | DB09130 | Copper | SmallMoleculeDrug |
| ENSG00000185624 | P4HB | DB11638 | Artenimol | SmallMoleculeDrug |
| ENSG00000185624 | P4HB | DB14487 | Zinc acetate | SmallMoleculeDrug |
| ENSG00000185624 | P4HB | DB14533 | Zinc chloride | SmallMoleculeDrug |
| ENSG00000185624 | P4HB | DB14548 | Zinc sulfate, unspecified form | SmallMoleculeDrug |
| Cancer therapeutic drugs associated with this gene(NCI). |
| Gene ID | Gene Name | Drug ID | Drug Name | Drug Type | Cancer |
Top |
Structure and expression level for P4HB |
| AS events and RNA A-to-I editing events of the gene in TCGA based on Genvode V22 structure. ∗For more information on exon skipping events please check the ExonskipDB database. ∗For more information on exon skipping events please check the CAeditome database. |
 |
| Landscape of gene expressions across multiple cancer types. |
 |
| Differentially expressed gene analysis between tumor male and tumor female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| Differentially expressed gene analysis between tumor male and normal male samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| P4HB | 5.64e+04 | 1.22e+00 | 1.71e-01 | 7.18e+00 | 7.08e-13 | 2.55e-11 | BLCA |
| Differentially expressed gene analysis between tumor female and normal female samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| P4HB | 6.56e+04 | 1.17e+00 | 1.58e-01 | 7.40e+00 | 1.37e-13 | 1.42e-12 | LUSC |
Top |
Sex-biased somatic mutation for P4HB |
| ∗For more information on exon skipping events please check the ExonskipDB database. |
| Gene ID | Cancer Type | Hugo Symbol | Male | Female | pval | or | ci.up | ci.low | adjPval |
Top |
DNA methylation with beta values for P4HB |
| Landscape of DNA methylation across multiple cancer types. |
 |
| Differentially expressed CpG sites between male tumor and female tumor patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| Differentially expressed CpG sites between male tumor and male normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| Differentially expressed CpG sites between female tumor and female normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
Top |
Exon skipping events with PSI in TCGA for P4HB |
| ∗Please access ExonSkipDB for exon skipping annotation. |
| Landscape of exon skipping events across multiple cancer types. |
 |
| Differentially expressed exon skipping events between male tumor and female tumor patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between male tumor and male normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between female tumor and female normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
Top |
RNA A-to-I editing events in TCGA for P4HB |
| ∗Please access CAeditome for RNA editing annotation. |
| Differentially expressed RNA editing events between male tumor and female tumor patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between male tumor and male normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between female tumor and female normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Protein coding RNA editing(s). |
| Editing Position | Variant Type | Gene Symbol | Transcript ID | NTchange | AAchange |
Top |
Sex-biased TF-Gene network for P4HB |
| TFs related to P4HB. ∗The female-biased TF-gene edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased TF-gene edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
| Cancer Type | TF | Target Gene | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| P4HB related gene. ∗Only the gene encode TF might with this result. ∗For more information please check Sex-biased TF-Coding gene network. |
Top |
Sex-biased RBP-ES network for P4HB |
| RBPs related to ES in P4HB. ∗The female-biased RBP-ES edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased RBP-ES edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
 |
| Cancer Type | RBP | Target ES | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| STAD | ANKHD1 | exon_skip_294580 | 1.44e+01 | 6.91e-04 | 1.51e+01 | 9.99e-01 | Female-biased |
| ACC | ANKHD1 | exon_skip_294580 | 1.58e+01 | 9.98e-01 | 1.51e+01 | 1.58e-03 | Male-biased |
| UVM | RBM46 | exon_skip_294576 | 1.24e+01 | 9.91e-01 | 1.21e+01 | 8.18e-03 | Male-biased |
| LIHC | SAMD4A | exon_skip_294605 | 8.43e+00 | 9.85e-01 | 8.00e+00 | 7.71e-03 | Male-biased |
| LIHC | SAMD4A | exon_skip_294607 | 8.47e+00 | 9.86e-01 | 8.04e+00 | 7.07e-03 | Male-biased |
| LUSC | SAMD4A | exon_skip_294605 | 8.23e+00 | 3.67e-03 | 8.68e+00 | 9.91e-01 | Female-biased |
| COAD | SAMD4A | exon_skip_294605 | 8.71e+00 | 9.81e-01 | 8.41e+00 | 1.35e-02 | Male-biased |
| BRCA | ANKHD1 | exon_skip_294580 | 1.49e+01 | 9.93e-01 | 1.43e+01 | 7.41e-03 | Male-biased |
| BRCA | FMR1 | exon_skip_294586 | 5.58e+00 | 2.54e-03 | 6.63e+00 | 9.80e-01 | Female-biased |
| BRCA | RBM46 | exon_skip_294576 | 1.15e+01 | 9.89e-01 | 1.10e+01 | 1.03e-02 | Male-biased |
| BRCA | SAMD4A | exon_skip_294592 | 6.84e+00 | 9.22e-03 | 7.50e+00 | 9.80e-01 | Female-biased |
| ESCA | SAMD4A | exon_skip_294605 | 8.88e+00 | 9.80e-01 | 8.49e+00 | 1.51e-02 | Male-biased |
| READ | SAMD4A | exon_skip_294605 | 8.13e+00 | 8.17e-04 | 8.70e+00 | 9.94e-01 | Female-biased |
| READ | SAMD4A | exon_skip_294607 | 8.22e+00 | 3.40e-03 | 8.65e+00 | 9.91e-01 | Female-biased |
| THCA | ANKHD1 | exon_skip_294580 | 1.50e+01 | 1.00e+00 | 1.44e+01 | 2.49e-04 | Male-biased |
| LGG | ANKHD1 | exon_skip_294580 | 1.39e+01 | 5.38e-04 | 1.46e+01 | 9.99e-01 | Female-biased |
| GBM | SAMD4A | exon_skip_294605 | 9.07e+00 | 9.94e-01 | 8.54e+00 | 1.41e-03 | Male-biased |
| GBM | SAMD4A | exon_skip_294607 | 8.99e+00 | 9.93e-01 | 8.51e+00 | 2.26e-03 | Male-biased |
| KICH | ANKHD1 | exon_skip_294580 | 1.53e+01 | 1.00e+00 | 1.47e+01 | 3.87e-04 | Male-biased |
| BLCA | ANKHD1 | exon_skip_294580 | 1.44e+01 | 9.30e-04 | 1.50e+01 | 9.99e-01 | Female-biased |
| BLCA | PCBP2 | exon_skip_294592 | 6.69e+00 | 9.81e-01 | 6.13e+00 | 1.88e-03 | Male-biased |
| SARC | ANKHD1 | exon_skip_294580 | 1.49e+01 | 9.98e-01 | 1.43e+01 | 1.44e-03 | Male-biased |
| SARC | SAMD4A | exon_skip_294592 | 7.31e+00 | 9.88e-01 | 6.49e+00 | 3.11e-04 | Male-biased |
| SARC | SAMD4A | exon_skip_294607 | 8.09e+00 | 2.72e-03 | 8.59e+00 | 9.91e-01 | Female-biased |
| P4HB related ES. ∗Only the gene encode RBP might with this result. ∗For more information please check Sex-biased RBP-ES network in cancer. |
Top |
Sex-biased CeRNA regulation of gene |
| Sex-biased CeRNA regulation of gene. |
| Gene ID | ceRNA(lncRNA-miRNA-mRNA) | Group | Cancer Type |
Top |
Sex-biased eQTL regulation of gene |
| Sex-biased eQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| eQTL | Description |
| Male-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs11872038 | chr17:81282457:G:A | - | 0.140447975881137 | 0.000374965632634164 | BLCA | Female-baised eQTL |
| rs346816 | chr17:76394857:A:G | - | 0.156218568994683 | 0.00309292251103591 | BLCA | Female-baised eQTL |
| rs346817 | chr17:76400405:G:A | - | 0.156218568994683 | 0.00309292251103591 | BLCA | Female-baised eQTL |
| rs453116 | chr17:76405722:C:A | - | 0.156218568994683 | 0.00309292251103591 | BLCA | Female-baised eQTL |
| rs346810 | chr17:76409032:G:A | - | 0.156218568994683 | 0.00309292251103591 | BLCA | Female-baised eQTL |
| rs346808 | chr17:76409204:G:A | - | 0.156218568994683 | 0.00309292251103591 | BLCA | Female-baised eQTL |
| rs381774 | chr17:76415706:G:A | - | 0.155516073242786 | 0.00340877047060171 | BLCA | Female-baised eQTL |
| rs1674350 | chr17:76416115:A:G | - | 0.155516073242786 | 0.00340877047060171 | BLCA | Female-baised eQTL |
| rs369654 | chr17:76420065:C:T | - | 0.155544635062854 | 0.00347173043051243 | BLCA | Female-baised eQTL |
| rs560924 | chr17:76420349:G:A | - | 0.155544635062854 | 0.00347173043051243 | BLCA | Female-baised eQTL |
| rs377253 | chr17:76417073:G:C | - | 0.155429120604032 | 0.0034737172223822 | BLCA | Female-baised eQTL |
| rs443112 | chr17:76417817:G:A | - | 0.155155633101204 | 0.00363207312928999 | BLCA | Female-baised eQTL |
| rs444896 | chr17:76425254:A:G | - | 0.133092565063804 | 0.0151534838987684 | BLCA | Female-baised eQTL |
| rs144685854 | chr17:76429091:G:A | - | 0.133092565063804 | 0.0151534838987684 | BLCA | Female-baised eQTL |
| rs12165049 | chr17:76435383:T:C | - | 0.133092565063804 | 0.0151534838987684 | BLCA | Female-baised eQTL |
| rs495055 | chr17:76444808:A:G | - | 0.133092565063804 | 0.0151534838987684 | BLCA | Female-baised eQTL |
| rs493035 | chr17:76445075:C:T | - | 0.133092565063804 | 0.0151534838987684 | BLCA | Female-baised eQTL |
| rs201664546 | chr17:76446469:A:C | - | 0.133092565063804 | 0.0151534838987684 | BLCA | Female-baised eQTL |
| rs619907 | chr17:76449694:G:A | - | 0.133092565063804 | 0.0151534838987684 | BLCA | Female-baised eQTL |
| rs28709924 | chr17:76452313:C:G | - | 0.133092565063804 | 0.0151534838987684 | BLCA | Female-baised eQTL |
| rs61040485 | chr17:73746991:C:T | - | 0.128695354136186 | 0.0152966193560551 | BLCA | Female-baised eQTL |
| rs28615986 | chr17:76455188:G:C | - | 0.137684029699262 | 0.0155137598135924 | BLCA | Female-baised eQTL |
| rs7222222 | chr17:77893530:C:T | - | 0.11246420055636 | 0.0194057442106033 | BLCA | Female-baised eQTL |
| rs499223 | chr17:76907528:T:G | - | 0.102905452353235 | 0.0281139112747145 | BLCA | Female-baised eQTL |
| rs582096 | chr17:76907695:T:C | - | 0.102905452353235 | 0.0281139112747145 | BLCA | Female-baised eQTL |
| rs1663458 | chr17:76909161:G:A | - | 0.0997983600192554 | 0.0331731052107756 | BLCA | Female-baised eQTL |
| rs532753 | chr17:76896772:A:C | - | 0.0994678602210407 | 0.0333286567242551 | BLCA | Female-baised eQTL |
| rs62077160 | chr17:76912138:C:T | - | 0.0955945461191955 | 0.0452530636887822 | BLCA | Female-baised eQTL |
| rs12150290 | chr17:72015278:A:C | - | -0.0847651352398413 | 0.0130201442881611 | LUAD | Female-baised eQTL |
| rs2193056 | chr17:72025410:T:C | - | -0.0643296045647636 | 0.0299492544120285 | LUAD | Female-baised eQTL |
| rs34567611 | chr17:72023499:A:G | - | -0.057643675129174 | 0.0439595386368867 | LUAD | Female-baised eQTL |
| Female-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs74000100 | chr17:82793264:T:G | - | 0.218229593028659 | 0.00148226506131738 | GBM | Male-baised eQTL |
| rs10512580 | chr17:71990271:C:A | - | 0.0626383403004396 | 0.0308040717793307 | LGG | Male-baised eQTL |
| rs56278251 | chr17:71991702:G:A | - | 0.0626383403004396 | 0.0308040717793307 | LGG | Male-baised eQTL |
| rs9909958 | chr17:71995735:G:A | - | 0.0626383403004396 | 0.0308040717793307 | LGG | Male-baised eQTL |
| rs2097958 | chr17:71996458:G:T | - | 0.0613753611067696 | 0.0439990836196729 | LGG | Male-baised eQTL |
| rs12450694 | chr17:71973590:T:A | - | 0.0605887368452488 | 0.0445308897978764 | LGG | Male-baised eQTL |
| rs12450214 | chr17:71973591:A:T | - | 0.0605887368452488 | 0.0445308897978764 | LGG | Male-baised eQTL |
| rs9914165 | chr17:72015688:A:T | - | 0.0609686934453093 | 0.0448869909518988 | LGG | Male-baised eQTL |
| rs11077587 | chr17:71969617:T:A | - | 0.0605420470617065 | 0.0449513813367967 | LGG | Male-baised eQTL |
| rs12450593 | chr17:71965149:C:G | - | 0.051733584645241 | 0.0295513934472804 | KIRC | Male-baised eQTL |
| rs7406694 | chr17:82469464:G:C | - | 0.0470862457377385 | 0.0400480771033386 | COAD | Male-baised eQTL |
| Opposite sex-biased eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Sex-biased Gene in Cancer | Cancer Type |
Top |
Sex-biased eQTM regulation of gene |
| Sex-biased eQTM regulation of gene (The figures only show the pairs with FDR<1e-5. For more information please check the below table). |
| eQTM | Description |
| Male-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| Female-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| Opposite sex-biased eQTM regulation. |
| CpG Site | CpG Postion | CpG Island | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Male Cor | Male P-value | Female Cor | Female P-value | Sex-biased Coding Gene | Cancer Type |
Top |
Sex-biased sQTL regulation of gene |
| Sex-biased sQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTL | Description |
| Male-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Female-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Opposite sex-biased sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Male Effect | Male FDR | Female Effect | Female FDR | Cancer Type |
Top |
Sex-biased sQTM regulation of gene |
| Sex-biased sQTM regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTM | Description |
| Male-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Female-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Opposite sex-biased sQTM regulation. |
| EX ID | EX Info | Skipped Exon | CPG Site | CPG Position | CPG Island | Position to EX Events | Male Effect | Male FDR | Female Effect | Female FDR | Male Correlation | Male P-value | Female Correlation | Female P-value | ORF_anno | Cancer Type |
Top |
Related disease information of P4HB |
| Diseases associated with this gene (DisGeNET). |
| Gene ID | Gene Symbol | Disease ID | Disease Name | Number of PMID | Source |
| ENSG00000185624 | P4HB | C0001787 | Osteoporosis, Age-Related | 1 | CTD_human |
| ENSG00000185624 | P4HB | C0019193 | Hepatitis, Toxic | 1 | CTD_human |
| ENSG00000185624 | P4HB | C0029456 | Osteoporosis | 1 | CTD_human |
| ENSG00000185624 | P4HB | C0029459 | Osteoporosis, Senile | 1 | CTD_human |
| ENSG00000185624 | P4HB | C0033578 | Prostatic Neoplasms | 1 | CTD_human |
| ENSG00000185624 | P4HB | C0151744 | Myocardial Ischemia | 1 | CTD_human |
| ENSG00000185624 | P4HB | C0376358 | Malignant neoplasm of prostate | 1 | CTD_human |
| ENSG00000185624 | P4HB | C0751406 | Post-Traumatic Osteoporosis | 1 | CTD_human |
| ENSG00000185624 | P4HB | C0860207 | Drug-Induced Liver Disease | 1 | CTD_human |
| ENSG00000185624 | P4HB | C1262760 | Hepatitis, Drug-Induced | 1 | CTD_human |
| ENSG00000185624 | P4HB | C1846707 | SPINOCEREBELLAR ATAXIA 17 | 1 | CTD_human |
| ENSG00000185624 | P4HB | C1862178 | Cole Carpenter syndrome | 1 | CTD_human |
| ENSG00000185624 | P4HB | C3658290 | Drug-Induced Acute Liver Injury | 1 | CTD_human |
| ENSG00000185624 | P4HB | C4277682 | Chemical and Drug Induced Liver Injury | 1 | CTD_human |
| ENSG00000185624 | P4HB | C4279912 | Chemically-Induced Liver Toxicity | 1 | CTD_human |
